Joan Levy, PhD, chief science officer at the Melanoma Research Alliance, discussed the significance of Tudriqev's accelerated approval for patients with anti-PD-1-refractory melanoma.
Joan Levy, PhD
Advertisement
Joan Levy, PhD, serves as the Chief Science Officer for the Melanoma Research Alliance
Articles by Joan Levy, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Dermatology Times
1
Oral IL-23 Blocker Icotrokinra Brings Biologic-Like Efficacy to Psoriasis
2
The Emerging Role of Oral Peptide Therapeutics in Psoriasis and Beyond
3
LEO Pharma Acquires Potential First Oral Therapy for EPP and XLP
4
HS Case Study: Closing Diagnostic Gaps in Adult Women
5